Market Overview
Colorectal cancer (CRC), also referred to as bowel cancer, is the development of malignant cells in the colon or rectum. It is the third most diagnosed cancer globally and the second leading cause of cancer-related deaths. Early-stage colorectal cancer is highly treatable, but many cases are diagnosed at an advanced stage due to limited access to or avoidance of routine colonoscopy screening.
According to the research report, the global colorectal cancer market was valued at USD 1.90 billion in 2023 and is expected to reach USD 2.88 billion by 2032, to grow at a CAGR of 4.80% during the forecast period.
Key Market Growth Drivers
- Rising Prevalence and Aging Population
Globally, the incidence of colorectal cancer is increasing, particularly among older adults. With longer life expectancies and an aging demographic, especially in developed regions, the number of people at risk for colorectal cancer continues to grow. Age remains a dominant risk factor, with most diagnoses occurring in individuals over 50.
The American Cancer Society estimates that by 2030, nearly 2.2 million new cases of CRC will be reported annually, underscoring the urgent need for improved screening and treatment solutions.
- Increased Emphasis on Colonoscopy Screening
Government initiatives and public health campaigns advocating for routine colonoscopy screening have led to earlier detection rates. In the United States and Europe, screening programs for individuals aged 45 and older are well established and have contributed to a measurable decline in mortality.
Emerging technologies such as virtual colonoscopy, fecal DNA testing (e.g., Cologuard), and AI-assisted diagnostic platforms are also improving access and accuracy, further fueling the market.
- Advancements in Targeted and Immunotherapies
The shift from conventional chemotherapy to targeted therapy and immunotherapy is a major market catalyst. Drugs targeting specific genetic mutations (such as KRAS, NRAS, and BRAF) or immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) have shown improved survival rates in certain patient populations.
For instance, Keytruda (pembrolizumab) and Opdivo (nivolumab) are increasingly used in microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancers. Combination regimens are under investigation to extend these benefits to a broader population.
- Development of Predictive Tumor Biomarkers
The identification and application of tumor biomarkers for prognosis, treatment selection, and monitoring are transforming oncology care. Genetic profiling and liquid biopsy technologies allow oncologists to detect mutations and monitor disease progression in real-time, enabling more precise, effective interventions.
The integration of oncology diagnostics with treatment regimens supports the growing emphasis on personalized medicine, which continues to expand the therapeutic market and improve clinical outcomes.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/global-colorectal-cancer-market
Market Challenges
- High Cost of Therapies and Diagnostics
Despite clinical advances, the high cost of targeted therapy, immunotherapy, and genetic testing remains a significant barrier, especially in low- and middle-income countries. Novel treatments can cost thousands of dollars per month, straining healthcare budgets and limiting patient access.
Health systems are under increasing pressure to balance innovation with affordability. Payers and insurers are implementing cost-control measures and outcome-based reimbursement models to ensure sustainable access to new therapies.
- Late Diagnosis in Developing Regions
In many parts of Asia, Africa, and Latin America, colorectal cancer is often diagnosed at advanced stages due to limited colonoscopy screening programs, inadequate public awareness, and poor access to healthcare. This significantly reduces survival rates and increases the complexity and cost of treatment.
To overcome this challenge, governments and NGOs must invest in public education, screening infrastructure, and training for primary care providers to detect early symptoms.
- Side Effects and Resistance to Therapies
While targeted therapy and immunotherapies are more specific than traditional chemotherapy, they are not without risks. Patients can develop resistance or experience serious side effects such as inflammation, autoimmune reactions, or organ toxicity.
Additionally, not all patients respond equally to immunotherapy, necessitating the development of new tumor biomarkers and combination regimens to improve efficacy and reduce resistance.
- Regulatory and Reimbursement Hurdles
Navigating complex regulatory landscapes for drug approvals and securing favorable reimbursement terms can delay product launches and market penetration. Companies must demonstrate not only safety and efficacy but also cost-effectiveness to gain acceptance.
Efforts to harmonize regulatory frameworks across borders and incorporate real-world evidence into evaluation processes are underway but remain a work in progress.
Regional Analysis
North America
North America dominates the global colorectal cancer market due to high disease prevalence, advanced healthcare systems, and widespread adoption of colonoscopy screening. The United States has robust screening guidelines, reimbursement policies, and access to cutting-edge therapies.
The region is also a leader in clinical research and innovation, with multiple biotech and pharmaceutical companies developing novel drugs, diagnostics, and digital health solutions.
Europe
Europe holds a significant market share, particularly in countries such as Germany, the UK, France, and the Netherlands. The presence of government-funded screening programs and strong regulatory support for innovation drives the region’s market growth.
The European Medicines Agency (EMA) has approved several targeted therapy agents and continues to support collaborative research initiatives across member states.
Asia-Pacific
The Asia-Pacific region is emerging as a high-growth market, driven by rising cancer prevalence, growing healthcare investments, and increased awareness. However, disparities in access to screening and treatment persist, particularly in rural and underserved areas.
Countries like Japan, China, South Korea, and Australia are making strides in adopting early detection strategies and approving new therapies. The region’s large patient population and expanding middle class offer significant long-term potential.
Latin America, Middle East, and Africa (LAMEA)
These regions remain underpenetrated due to systemic healthcare challenges. Low screening rates, limited insurance coverage, and lack of diagnostic infrastructure impede progress.
However, international health initiatives, growing private sector investment, and government reforms are gradually improving access and building capacity, particularly in urban centers.
Key Companies in the Colorectal Cancer Market
- F. Hoffmann-La Roche Ltd.
Roche leads in oncology diagnostics and targeted therapies with products like Avastin (bevacizumab) and companion diagnostics. The company continues to invest in biomarker research and personalized medicine strategies.
- Merck & Co., Inc.
Merck’s Keytruda has shown promise in treating MSI-H colorectal cancer, particularly in advanced stages. Ongoing clinical trials are evaluating combination regimens to expand indications.
- Amgen Inc.
Amgen offers Vectibix (panitumumab), a monoclonal antibody targeting the EGFR pathway, approved for KRAS wild-type metastatic colorectal cancer. The company is also active in biosimilar development.
- Bristol Myers Squibb
BMS is expanding its immuno-oncology portfolio with Opdivo and Yervoy, approved for specific subsets of colorectal cancer patients. Research continues into combination immunotherapy for enhanced efficacy.
- Guardant Health & Exact Sciences
Both companies are at the forefront of tumor biomarkers and non-invasive diagnostics. Exact Sciences’ Cologuard test offers an FDA-approved at-home screening alternative, while Guardant Health leads in liquid biopsy technology.
- Pfizer Inc.
Pfizer collaborates on multiple targeted therapy pipelines and combination regimens for colorectal and other GI cancers. The company’s global reach supports widespread access and regulatory navigation.
Conclusion
The colorectal cancer market is undergoing a paradigm shift as scientific innovation and public health efforts converge to improve early detection, personalize treatments, and enhance survival. From improved colonoscopy screening to breakthroughs in targeted therapy and the discovery of new tumor biomarkers, the landscape is evolving rapidly.
More Trending Latest Reports By Polaris Market Research:
Myasthenia Gravis Disease Market
Blood Glucose Monitoring Device Market
Multiparameter Patient Monitoring Market
Meningitis Diagnosis and Treatment Market
Prosthetics And Orthotics Market
Nonmydriatic Fundus Cameras Market
Veterinary Surgical Procedures Market
Orthopedic Surgical Robots Market
Laboratory Developed Tests Market
Understanding Managed Care Industry: A Comprehensive Overview
Journey of Bioprocessing Analytics Equipment from Lab to Market